Aromatase inhibitors therapy has radically changed the prognosis of hormone receptor positive BC in post-menopausal women in the last thirty years, and is still a mainstay of therapy in the adjuvant and advanced stage settings [186]. This evidence concerns the gene CYP19A1 and breast cancer.